The risk of mortality and the factor V Leiden mutation in a population-based cohort

Thrombosis and Haemostasis

Volumn 80, Issue 4, 1998, Pages 607-609

  Heijmans, Bastiaan T ^a,b   Westendorp, Rudi G J ^b   Knook, Dick L ^a,b   Kluft, Cornelis ^a   Slagboom, P Eline ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DISEASE ASSOCIATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK; RISK FACTOR; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FACTOR V; HUMANS; PREVALENCE; RISK; THROMBOSIS;

EID: 0031786802     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
2. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Eng J Med 1995; 332: 912-7.
3. Griffin JH, Heeb MJ, Kojima Y, Fernandez JA, Kojima K, Hackeng TM, Greengard JS. Activated protein C resistance: molecular mechanisms. Thromb Haemost 1995; 74: 444-8.
4. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to GIn factor V mutation and activated protein C resistance. Lancet 1995; 345: 321.
5. Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995; 1: 185.
6. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Long-streth WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
7. Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thrombosis among heterozygous carriers of factor V Leiden mutation. Ann Int Med 1997; 126: 528-31.
8. Lagaay A M, D'Amaro J, Ligthart G J, Schreuder G M T, Van Rood JJ, Hijmans W. Longevity and heredity in humans: Association with Human Leucocyte Antigen phenotype. Ann N Y Acad Sci 1991; 621: 78-89.
9. Weverling-Rijnsburger AWE, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and the risk of mortality in the oldest old. Lancet 1997; 350: 1119-23.
10. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of the factor V Leiden mutation. Lancet 1994; 344: 1453-7.
11. Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996: 76: 510-3.
12. Martinelli I, Cattaneo M, Panzeri D, Mannucci PM. Low prevalence of Factor V:Q506 in 41 patients with isolated pulmonary embolism. Thromb Haemost 1997; 77: 440-3.
13. Baglin TP, Brown K, Williamson D, Baker P, Luddington R. Relative risk of pulmonary embolism and deep vein thrombosis in association with the factor V Leiden mutation in a United Kingdom population. Thromb Haemost 1997; 77: 1219.
14. Vandenbroucke JP, Bertina RM, Holmes ZR, Spaargaren C, Van Krieken JHJM, Manten B, Reitsma PH. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998; 79: 511-6
15. Hille ETM, Westendorp RGJ, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89: 1963-7.
16. Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C. Mutant factor V (Arg506GIn) in healthy centenaríans. Lancet 1996; 347: 1044.
17. Faure-Delanef L, Quéré I, Zouali H, Cohen D. Human longevity and R506Q factor V gene mutation. Thromb Haemost 1997; 78: 1160.
18. Van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.